Menu
Search
|

Menu

Close
X

Vanda Pharmaceuticals Inc VNDA.OQ (NASDAQ Stock Exchange Global Market)

22.62 USD
-1.19 (-5.00%)
As of 3:59 PM EST
chart
Previous Close 23.81
Open 23.88
Volume 307,065
3m Avg Volume 290,525
Today’s High 24.04
Today’s Low 22.48
52 Week High 25.07
52 Week Low 11.90
Shares Outstanding (mil) 52.38
Market Capitalization (mil) 1,247.16
Forward P/E 99.54
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
140
FY17
165
FY16
146
FY15
110
EPS (USD)
FY18
0.280
FY17
-0.349
FY16
-0.417
FY15
-0.942
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
99.54
29.57
Price to Sales (TTM)
vs sector
6.77
15.43
Price to Book (MRQ)
vs sector
4.77
4.06
Price to Cash Flow (TTM)
vs sector
78.02
21.23
Total Debt to Equity (MRQ)
vs sector
0.00
14.84
LT Debt to Equity (MRQ)
vs sector
0.00
11.13
Return on Investment (TTM)
vs sector
6.51
12.77
Return on Equity (TTM)
vs sector
6.64
14.47

EXECUTIVE LEADERSHIP

H. Thomas Watkins
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Mihael Polymeropoulos
President, Chief Executive Officer, Director, Since 2010
Salary: $675,000.00
Bonus: $502,200.00
James Kelly
Chief Financial Officer, Executive Vice President, Treasurer, Since 2017
Salary: $465,000.00
Bonus: $216,225.00
Gian Reverberi
Senior Vice President, Chief Compliance Officer, Since 2016
Salary: $486,553.00
Bonus: $203,622.00
Timothy Williams
Senior Vice President, General Counsel, Secretary, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2200 Pennsylvania Ave NW Ste 300
WASHINGTON   DC   20037-1754

Phone: +1202.7343400

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.

SPONSORED STORIES